Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients-Reference-Cited by-同舟云学术

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Published:2016-03-13 Issue:5 Volume:46 Page:462-467
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:Jpn. J. Clin. Oncol.

Author:

Inoue Akira,Yoshida Kazushi,Morita Satoshi,Imamura Fumio,Seto Takashi,Okamoto Isamu,Nakagawa Kazuhiko,Yamamoto Nobuyuki,Muto Satoshi,Fukuoka Masahiro

Funder

AstraZeneca

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/46/5/462/6826699/hyw014.pdf

Reference29 articles.

1. The Japan Lung Cancer Society. Japan Guidelines of Lung Cancer Therapy. 2014 ed. Japan: Kanehara Shuppan 2014.

2. EGFRMutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

3. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

4. Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR);Yoshioka;J Clin Oncol,2014

5. Phase II trial to evaluate Erlotinib as a 1st line treatment to NSCLC with EGFR mutation: overall survival of JO22903;Katakami;Haigan,2014

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study;Drugs - Real World Outcomes;2024-08-29

2. Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC;JTO Clinical and Research Reports;2024-08

3. Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy;JMIR Research Protocols;2024-07-02

4. Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib;Current Oncology;2024-04-26

5. Patient Age andEGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study;Anticancer Research;2024-03-27